Trinidad Makes History with First Oncology Clinical Trial Amidst Pandemic Challenges

Trinidad's Pioneering Step in Oncology Clinical Trials

In an unprecedented move, Trinidad and Tobago successfully conducted its first oncology clinical trial, a significant achievement for the Caribbean nation. This milestone was reached amidst the global COVID-19 pandemic, showcasing the resilience and ingenuity of the medical community.

A Journey of Hope and Innovation

Faithanne Hill, a 22-year-old Trinidadian diagnosed with stage 4 alveolar soft part sarcoma (ASPS), became the first patient to receive an investigational agent in her home country for an oncology clinical trial. ASPS, an ultrarare soft tissue sarcoma, has a global incidence of less than 1 per 1,000,000, making Faith's case exceptionally unique.

Faith's journey began in 2013 when she was misdiagnosed with rhabdomyosarcoma, a more common type of sarcoma in Trinidad. After the correct diagnosis, her parents sought help from the National Cancer Institute (NCI) in the United States, leading to her participation in various clinical trials, including those for cediranib and sunitinib (Sutent).

Overcoming Pandemic Barriers

The COVID-19 pandemic posed a significant challenge when Trinidad's borders closed in March 2020, preventing Faith from traveling to the U.S. for her ongoing phase II trial of atezolizumab (Tecentriq). In response, a collaborative effort between the NCI, Trinidad's Ministry of Health, and local healthcare professionals ensured that Faith could continue her treatment in Trinidad.

This required accrediting a local laboratory facility, health center, pharmacy, radiologist, and oncologist by both the NIH and Trinidad's ethics review process. The Ministry of Health also worked with the Customs and Excise Department to facilitate the shipment of treatments into the country.

A Model for Global Clinical Trials

The success of this trial has broader implications for clinical research, demonstrating that middle-income countries can contribute significantly to global medical advancements. The trial's data contributed to the U.S. Food and Drug Administration's approval of atezolizumab for ASPS in December 2022.

Researchers involved in the trial have advocated for a more inclusive approach to clinical trials, emphasizing the importance of global participation, especially for rare diseases. This initiative highlights the potential for increased patient participation from developing and middle-income countries, reducing disparities in access to cutting-edge treatments.

Looking Ahead

The trial's success in Trinidad has set a precedent for future clinical research in the region, encouraging the establishment of more systems to facilitate such trials. It underscores the need for investment in training and infrastructure to support clinical research in developing nations, ultimately benefiting patients worldwide.

Faith's story is not just one of personal triumph but also a beacon of hope for patients in similar situations, proving that with determination and collaboration, barriers to treatment can be overcome, even in the most challenging circumstances.